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Mutations in BICD2, which Encodes a Golgin
and Important Motor Adaptor, Cause Congenital
Autosomal-Dominant Spinal Muscular Atrophy
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Rowdy Meijer,1 Margot te Riele,7 Catharina J.M. Frijns,8 Oksana Suchowersky,9 Linda MacLaren,10
Sabine Rudnik-Scho¨neborn,11 Richard J. Sinke,12 Klaus Zerres,11 R. Brian Lowry,10
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Spinal muscular atrophy (SMA) is a heterogeneous group of neuromuscular disorders caused by degeneration of lower motor neurons.
Although functional loss of SMN1 is associated with autosomal-recessive childhood SMA, the genetic cause for most families affected by
dominantly inherited SMA is unknown. Here, we identified pathogenic variants in bicaudal D homolog 2 (Drosophila) (BICD2) in
three families afflicted with autosomal-dominant SMA. Affected individuals displayed congenital slowly progressive muscle weakness
mainly of the lower limbs and congenital contractures. In a large Dutch family, linkage analysis identified a 9q22.3 locus in which exome
sequencing uncovered c.320C>T (p.Ser107Leu) in BICD2. Sequencing of 23 additional families affected by dominant SMA led to the
identification of pathogenic variants in one family from Canada (c.2108C>T [p.Thr703Met]) and one from the Netherlands
(c.563A>C [p.Asn188Thr]). BICD2 is a golgin andmotor-adaptor protein involved inGolgi dynamics and vesicular andmRNA transport.
Transient transfection of HeLa cells with all three mutant BICD2 cDNAs caused massive Golgi fragmentation. This observation was even
more prominent in primary fibroblasts from an individual harboring c.2108C>T (p.Thr703Met) (affecting the C-terminal coiled-coil
domain) and slightly less evident in individuals with c.563A>C (p.Asn188Thr) (affecting the N-terminal coiled-coil domain). Further-
more, BICD2 levels were reduced in affected individuals and trapped within the fragmented Golgi. Previous studies have shown that
Drosophilamutant BicD causes reduced larvae locomotion by impaired clathrin-mediated synaptic endocytosis in neuromuscular junc-
tions. These data emphasize the relevance of BICD2 in synaptic-vesicle recycling and support the conclusion that BICD2 mutations
cause congenital slowly progressive dominant SMA.Neurodegenerative or developmental disorders affecting
motor neurons, their axons, or the presynapse at the
neuromuscular junction (NMJ) produce a large spectrum
of inherited diseases, including spinal muscular atrophies
(SMAs), which partially overlap with hereditary motor
neuropathies (HMNs), and amyotrophic lateral sclerosis
(ALS).1–4 The term SMA (MIM 253300 for type I, MIM
253550 for type II, MIM 253400 for type III, and MIM
271150 for type IV) is used for the most frequent auto-
somal-recessive proximal SMA linked to chromosomal re-
gion 5q13.15 and as a general label for a group of non-5q
SMAs characterized by anterior horn cell loss and progres-
sive muscle weakness and atrophy without sensory neuron
involvement.6 The underlying molecular defect of auto-
somal-recessive proximal SMA is the functional loss of sur-
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ses of spinal a-motor neurons.5,7 On the basis of age of
onset, pattern of muscle involvement, and inheritance,
approximately 30 additional genetic entities for SMA
and/or HMN have been described (World Federation of
Neurology Research Committee and Online Mendelian
Inheritance in Man). Among these entities, mutations in
12 genes have been identified to cause autosomal-domi-
nant forms of SMA and/or HMN—these include GARS
(MIM 600287),8 DCTN1 (MIM 601143),9 HSPB8 (MIM
608041),10 HSPB1 (MIM 602195),11 BSCL2 (MIM
606168),12 SETX (MIM 608465),13 VAPB (MIM 605704),14
HSPB3 (MIM 604624),15 TRPV4 (MIM 605427),16
DYNC1H1 (MIM 600112),17 REEP1 (MIM 609139),18 and
SLC5A7 (MIM 608761).19 Mutations in each of these genes
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Figure 1. Identified BICD2 Mutations
and Their Chromosomal Positions
(A, E, and G) Pedigrees of families 1 (A), 2
(E), and 3 (G).
(B) An ideogram of chromosome 9 shows
the linked region and the flanking SNPs
identified in family 1.
(C) An ideogram of BICD2 includes exon
and intron structure and the identified
variants.
(D, F, and H) A sequence of the region
includes themutation and the correspond-
ing region of the unaffected parent in fam-
ilies 1 (D), 2 (F), and 3 (H).molecular genetic basis is only known in fewer than 30%
of individuals with dominant SMA and/or HMN.20 Many
different processes—such as inhibition of microtubule-
based dynein-mediated intracellular and axonal transport,
inhibition of the ubiquitin-proteasome system, impaired
RNA metabolism, protein aggregation or Ca2þ homeosta-
sis, oxidative and nitrosative stress, redistribution of pro-
teins from the nucleus to the cytoplasm, fragmentation
of the Golgi apparatus, and dysfunction of mitochon-
dria—underlie motor neuron degeneration or disturbed
motor neuron development, as reviewed.6,20,21 Here, we
identify bicaudal D homolog 2 (Drosophila) (BICD2 [MIM
609797]) mutations that cause autosomal-dominant SMA
by affecting Golgi integrity. Our data emphasize the impor-
tant role of BICD2, a protein known to be essential in the
retrograde and anterograde transport along the microtu-
bules, for the functional integrity of lower motor neurons.
Frijns and colleagues reported a Dutch family affected by
an autosomal-dominant congenital benign SMA22 (familyThe American Journal of Huma1, Figure 1A), for which we identified
the underlying genetic cause, present-
ing the initial fuse for this study. In
this three-generation Dutch family,
seven affected individuals have been
reported with similar features of prox-
imal and distal muscle weakness and
atrophy of the lower limbs and
congenital contractures of the ankles
and feet. They presented with a
waddling gait and were able to walk
on toes, but not on heels. Muscle bi-
opsies showed neurogenic changes.
Serum creatine kinase (CK) activity
was normal or marginally raised.
Motor nerve conduction studies
including speed and amplitude ofmo-
tor nerve conduction velocity (NCV)
and compound muscle action poten-
tial showed results in the normal
range. Sensory NCVs were also
normal or near normal. These find-
ings are in favor of a motor neuron
disease and argue against an axonalneuropathy.22 A recent examination of individuals II.6
and III.3, nearly 20 years later, revealed an almost un-
changed phenotype, except for more severe muscle
cramps, emphasizing the nonprogressive form of this dis-
ease.
For identifying the chromosomal location of the under-
lying disease-causing mutation, a genome-wide linkage
analysis was performed in nine family members (family
1, Figures 1A and 1B), from whom written informed con-
sent was obtained. Linkage was performed as described pre-
viously23 and identified a locus with a maximum multi-
point LOD score of 2.065 between SNP_A-1510343 and
SNP_A-1514261 on chromosome 9 (chr9: 94,440,951–
104,432,543). This nearly 10 Mb chromosomal segment
(Figure 1B) contains approximately 50 genes.
Subsequently, exome sequencing was performed in a sin-
gle affected individual (III.2, family 1, Figure 1A) on a
SOLiD4 sequencing platform from Life Technologies
(Carlsbad, CA, USA). The exome of the proband wasn Genetics 92, 946–954, June 6, 2013 947
Figure 2. Schematic Drawing of BICD2
and Its Interaction Partners
The diagram depicts a simplified structure
of human BICD2. Indicated are the five
coiled-coil domains, which are typically
combined as coiled-coil domains 1–3.
Numbers indicate the respective amino
acid residues. In the upper part of the dia-
gram, known interaction partners of the
respective coiled-coil domains are given.
Please note that the interaction with
FMRP is RNAmediated and the interaction
between clathrin heavy chain (CLHC) and
BICD2 has only been shown forDrosophila
so far. In the lower part of the diagram, the
four identified variants and a multispecies
alignment of the affected amino acids are
given. Protein sequences were aligned
with blastp.enriched according to themanufacturer’s protocol with the
use of Agilent’s SureSelect Human All Exon v.2 Kit (50 Mb),
which contains the exonic sequences of approximately
21,000 genes (Agilent Technologies, Santa Clara, CA,
USA). LifeScope software v.2.1 from Life Technologies was
used for mapping color-space reads along the UCSC
Genome Browser (hg19) reference genome assembly. The
DiBayes algorithm, with high-stringency calling, was
used for single-nucleotide variant (SNV) calling. The small
indel tool was used for detecting small insertions and dele-
tions. Exome-sequencing data were filtered as described
previously.24 Exome sequencing showed 503 median
coverage. In total, 118,859,416 reads were obtained, and
96,800,227 of them could be mapped to the human
genome (hg19). Variant calling resulted in a total of
27,190 variants. Filtering for variants located on chromo-
some 9 reduced this number to 1,064 variants. Further
filtering was performed for obtaining nonsynonymous
exonic and splice-site variants. After combined exclusion
of known SNPs (dbSNP129) and of variants that had been
identified previously and summarized in an in-house data-
base,24 just five variants in five different genes remained
(Tables S1 and S2, available online). Of these five genes,
only BICD2 (RefSeq accession number NM_001003800.1)
was located within the linkage region (Table S2 and Figures
1B and 1C). The detected variant (g.95491439C>T
[c.320C>T]), localized within a CpG dinucleotide, affects
a highly conserved serine residue (phyloP 3.65) and results
in the amino acid change p.Ser107Leu. The effect of this
amino acid change is predicted to be deleterious by SIFT25
and probably damaging by PolyPhen-226 (Table S3). These
findings, together with the presence of variant c.320C>T
in five tested affected individuals but in none of four tested
unaffected relatives as shown by Sanger sequencing
(Figure 1D), strongly support the view that this is the caus-
ative damaging mutation in this family.
To search for further BICD2 variants that might cause
dominant SMA, we analyzed all seven exons by Sanger948 The American Journal of Human Genetics 92, 946–954, June 6, 2sequencing in 23 additional families affected by auto-
somal-dominant SMA. Informed consent was obtained
from affected individuals and relatives, and the study was
approved by the local ethical committee in Cologne. Het-
erozygous variants in BICD2 were identified in two addi-
tional families. First, in a previously described Canadian
family (family 2, Figure 1E) affected by congenital auto-
somal-dominant distal SMA,27 both affected family mem-
bers—father and son—carried the heterozygous missense
variant, c.2108C>T (p.Thr703Met), localized within a
CpG dinucleotide in exon 6 (Figures 1C and 1F). Second,
we identified another Dutch family (family 3, Figure 1G)
comprising five affected and four unaffected individuals,
and all affected individuals, but none of the unaffected
individuals, were heterozygous for variant c.563A>C
(p.Asn188Thr) (Figures 1C and 1H). The Canadian
p.Thr703Met substitution was located in the fifth coiled-
coil domain (C-terminal part) of BICD2, whereas the
Dutch p.Asn188Thr substitution was located in the second
coiled-coil domain (N-terminal part) of BICD2 (Figure 2).
Both amino acid positions (Thr703 and Asn188) are highly
conserved throughout 46 vertebrate species (PhyloP 5.49
and 4.25, respectively) (UniProt and Figure 2), and the
substitutions are predicted to be damaging by SIFT and
PolyPhen-2 (Table S3). Moreover, the three variants (the
two Dutch and one Canadian) were not found in the
1,094 genomes of the 1000 Genomes database, the 6,500
exomes of the National Heart, Lung, and Blood Institute
(NHLBI) Exome Sequencing Project Exome Variant Server
(EVS), an in-house database comprising 1302 exomes, or
dbSNP137.
In addition, a rare SNV (c.269A>G [p.Lys90Arg];
rs61754130), localized in exon 2 of BICD2 was identified
twice in our cohort of 23 independent SMA-affected fam-
ilies with dominant inheritance (Figure 1C). The minor
allele frequency of this variant is 0.004 in the EVS and
0.0009 in dbSNP. We further performed segregation ana-
lysis in all available affected and unaffected members of013
these two families, which are both of German origin. The
same variant was identified in one additional affected indi-
vidual of one family but only in two out of four affected in-
dividuals of the second family, excluding the c.269A>G
variant as the causative mutation (data not shown). Never-
theless, we cannot fully exclude a potential modifying role
given that amino acid Lys90 is moderately conserved
(Figure 2).
Furthermore, the entire coding region of the paralogous
BICD1 was analyzed in those families in which no BICD2
mutation was found. No mutations were found in BICD1
either.
The phenotype described by Adams and colleagues for
the Canadian family,27 harboring amino acid substitution
p.Thr703Met, very much resembles that of the first Dutch
family.22 Both father and son had congenital foot defor-
mities and muscle weakness and atrophy of the lower
limbs and mild proximal and hand intrinsic weakness.
Knee and ankle tendon reflexes were absent. CK levels
were normal, and both NCVs and amplitude of motor
and sensory responses were normal. Both electromyog-
raphy (EMG) and muscle biopsy showed chronic neuro-
genic changes.27 Both individuals were recently reex-
amined and showed no noticeable changes.
In the second Dutch family with the p.Asn188Thr
substitution, two individuals (II.2 and III.1) belonging to
a three-generation pedigree with six affected individuals
(Figure 1G) were extensively clinically investigated.
Together with her affected daughter, III.1, individual II.2
was seen for the first time at the age of 35 years. Individual
II.2 had delayed motor development but did not mention
muscle complaints, sensory disturbances, or exercise intol-
erance. Family history revealed a muscle disorder in two of
her siblings and her mother. Neurological examination
revealed mild atrophy of proximal limb muscles, muscle
strength was mildly lowered (shoulder muscles scored a
4/5 on the Medical Research Council [MRC] scale for mus-
cle strength), and she was unable to walk on her heels.
Gowers’ sign was absent, but she had a waddling gait.
Examination of sensory and cranial nerves and coordina-
tion were normal. She had generalized hyperreflexia with
indifferent plantar responses. EMG showed a chronic
neurogenic pattern. After 10 years, follow-up examination
showed mild atrophy of deltoid muscles. Muscle tone was
normal. Muscle strength was mildly diminished: MRC
scale scores were 4/5 for shoulder abductors, 4/5 for biceps
muscles, and 3/5 for tibial, peroneal, and extensor hallucis
longus muscles. She still had a mild waddling gait, and
Gowers’ sign was absent. Examination of cranial nerve
function revealed a hoarse voice, and sensory function
and coordination were normal. Tendon reflexes of the
upper limbs were lowered, and knee tendon reflexes were
exaggerated: there was a moderate crossed adductor
response on the left knee with an absence of an ipsi-
lateral response on the right and a minimal crossed
adductor response on the right knee. The Achilles tendon
reflexes were absent, and extensor responses were indif-The Amferent. Furthermore, she reported that her niece (III.3)
was affected as well.
Her daughter (III.1) was seen for the first time at the age
of 2 years and 11 months. The gestation period was
complicated by oligohydramnios, and she was born with
vacuum extraction. She was treated for congenital hip
dysplasia from 4 to 7 months of age. She was able to sit
without support from the age of 7.5 months and was
able to walk without support at the age of 20 months.
Neurological examination showed mild atrophy of prox-
imal limb muscles, and muscle strength was mildly low-
ered (shoulder abductors scored a 4/5 on the MRC scale)
with scapulae alatae and lumbar hyperlordosis. Cranial
nerve function was normal. While walking, she showed a
waddling gait and Gowers’ sign. Sensory function and
coordination were normal. She had generalized hyperre-
flexia, more pronounced on the legs, and bilateral patho-
logic plantar responses. EMG was normal. Follow-up after
2 years (when she was almost 5 years old) showed a
waddling gait and an inability to jump. Muscle strength
of the arms was mildly affected: the bilateral proximal
and distal grade was 4/5. Proximal muscle strength of the
legs was 4/5, and distal was 2/5. Since early childhood,
she has worn ankle-foot orthoses during the night to pre-
vent calf muscle contractures (which were not present at
examination). When she was 12 years and 9 months old,
follow-up examination showed mild atrophy of deltoid
muscles. Muscle tone was normal. Muscle strength was
mildly diminished: MRS scale scores were 4/5 for shoulder
abductors, 4/5 for biceps muscles, and 3/5 for tibial, pero-
neal, and extensor hallucis longus muscles. She still had
a waddling gait, and Gowers’ sign was absent. Cranial
nerve function and sensory function and coordination
were normal. Tendon reflexes of the upper limbs were
normal, knee tendon reflexes were increased, Achilles
tendon reflexes were lowered, and extensor responses
were plantar. She needed special education because of a
learning disorder.
No clinical data were available from the affected grand-
mother. It has only been reported that she had muscle
weakness. The other three affected individuals (II.3, II.5,
and III.3) all had congenital hip dysplasia, and affected in-
dividual III.3 additionally had bilateral club feet. Affected
individuals II.3 and II.5 were able to walk at 18 months
of age but developed mild muscle atrophy and weakness
in early childhood (especially of the proximal muscles of
the legs) and hyperreflexia with bilateral indifferent
plantar responses, whereas affected individual III.3 was un-
able to walk at the age of 18 months. She hadmild atrophy
of proximal limb muscles, and muscle strength was mildly
reduced, no hyperreflexia was present, and plantar re-
sponses were normal. In all three affected individuals,
EMG showed neurogenic changes. Muscle biopsy from
the quadriceps of individuals II.3 and II.5 showed a neuro-
genic pattern.
BICD2 (MIM 609797) is homologous toDrosophila bicau-
dal D (BicD), which is evolutionarily conserved from flieserican Journal of Human Genetics 92, 946–954, June 6, 2013 949
to humans (UniProt). Although flies have one BicD gene,
mammals have two paralogous genes: BICD1 (MIM
602204), which is localized in chromosomal region
12p11.2–p11.1 and whose encoded protein is mainly
expressed in brain, skeletal muscle, and heart,28 and
BICD2, which is localized in chromosomal region 9q22.3
and encodes a ubiquitously expressed protein. BICD2 is a
cytoplasmic conserved motor-adaptor protein involved
in anterograde and retrograde transport.29 BICD2, consid-
ered a golgin, has roles in the synaptic vesicle and mem-
brane traffic and Golgi structure (reviewed in Goud and
Gleeson30). Most importantly, third instar larvae of zygotic
BicDmutants in Drosophila show a reduced rate of locomo-
tion during active bouts of crawling by impaired clathrin-
mediated synaptic-vesicle recycling.31 Panneuronal
expression of BicD fully rescued larval locomotion and
lethality of the mutants, whereas expression in the muscle
did not, emphasizing its important role in the nervous
system.
BICD2 is a highly versatile molecule with five coiled-coil
domains (Figure 2). The N-terminal domain of BICD2 reg-
ulates the recruitment of dynein and promotes stable inter-
action between dynein and dynactin.32–34 The in vitro
overexpression of the N-terminal domain of BICD2 has
been reported to cause Golgi fragmentation.32–34 In line
with these findings, transgenic mice expressing the N ter-
minus of BICD2 (BICD2-N) show Golgi fragmentation,
axonal neurofilament swelling, and reduced retrograde
transport.35 Alterations in the dynein-dynactin motor
complex are considered to be involved in neuron degener-
ation. Mutations in DCTN1 (MIM 601143), encoding the
largest subunit (p150Glued) of dynactin, have been associ-
ated with a slowly progressive, autosomal-dominant form
of lower motor neuron disease without sensory symptoms
(HMN7B [MIM607641]) andwith ALS.9,36 After 10months
of age, heterozygous knockin mice of mutant DCTN1
(c.957C>T [p.Gly59Ser]) display motor-neuron-disease-
like phenotypes, including excessive accumulation of
cytoskeletal and synaptic-vesicle proteins at NMJs, loss of
spinal motor neurons, increase in reactive astrogliosis,
and shortening of gait.37 The central part of BICD2 inter-
acts with another important motor protein, the neuronal
kinesin heavy-chain protein KIF5A.29 Mutations in KIF5A
(MIM 602821) cause hereditary spastic paraplegia (HSP)
type 10 (SPG10 [MIM 604187]), an autosomal-dominant
HSP.38,39 Knockout of Kif5a inmice causes reduced survival
of motor neurons, which reveal a significant deficit in
axonal and dendritic outgrowth and impaired anterograde
axonal transport, whereas sensory neurons are spared.38,39
The C-terminal third of BICD2mediates transport of a sub-
set of cargos, including Golgi vesicles, lipid droplets,
nuclei, and specific mRNAs.40,41 The C-terminal part of
BICD2 directly interacts with dynactin subunit p50 dyna-
mitin (DCTN2). The Drosophila BicD C terminus directly
interacts with the clathrin heavy chain, which has been
shown to facilitate and be essential to clathrin-mediated
endocytosis at the NMJ level.31–34 Furthermore, BICD2 is950 The American Journal of Human Genetics 92, 946–954, June 6, 2targeted to the trans-Golgi network via the interaction be-
tween its C-terminal domain and the small GTPase
RAB6A.32–34 Experimental evidence suggests that the C ter-
minus inhibits the recruitment of the dynein-dynactin
complex by the N terminus, implying a regulatory effect
of both domains.32–34 Finally, BICD2 also has a role in
the positioning of the nucleus and centrosomes in mitotic
cells. During the G2 phase, the C terminus of BICD2
switches from the interacting partner RAB6A to RANBP2,
a component of the nuclear pore. Interestingly, RANBP2
has been reported to also directly interact with KIF5B and
KIF5C, supporting the notion that it is involved in micro-
tubule motor recruitment.42 Depletion of BICD2 inhibits
both dynein- and kinesin-1-dependent movements of
the nucleus and cytoplasmic nucleopore complexes,
demonstrating that BICD2 is essential for both retrograde
and anterograde transport.29
Given that BICD2 plays an important role in Golgi dy-
namics and targeting,34 we investigated a possible effect
of the identified BICD2 mutations on the integrity of the
Golgi apparatus. For each variant, we generated a turbo
GFP (tGFP)-BICD2 fusion protein by using the wild-type
BICD2 cDNA and site-directed mutagenesis to introduce
the respectivemutations. All clones were Sanger sequenced
for verification of the introduced mutation. HeLa cells
were transiently transfected with each of the five tGFP-
BICD2 plasmids (the wild-type, the three mutations, and
the rare variant) and immunostained against Giantin, a
conserved Golgi membrane marker,43 and with DAPI for
visualization of the nucleus. The tGFP to which BICD2
was fused allowed us to easily distinguish transfected
from nontransfected cells. Whereas the transient expres-
sion of the wild-type tGFP-BICD2 protein had no impact
on Golgi integrity, the transfected cells with altered
BICD2 showed very faint, few, or dispersed Giantin signals
in the transfected cells compared to the surrounding non-
transfected cells, suggestingGolgi fragmentation (Figure 3).
Rare variant c.269A>G (p.Lys90Arg) showed only slightly
fainter and more disorganized Golgi staining than did
the control, so we cannot fully exclude a potential modi-
fying effect (Figure 3).
Next, the effect of the pathogenic BICD2 was investi-
gated in primary fibroblast cells established from skin bi-
opsies from a Canadian affected individual harboring the
p.Thr703Met substitution and a Dutch affected individual
harboring the p.Asn188Thr substitution. As shown by
immunoblot analysis, BICD2 levels were lower in fibro-
blasts of affected individuals than in control fibroblasts
by a so far unknown mechanism (Figures 4A and 4B). Im-
munostainings with BICD2 antibody and two different
Golgi markers, p230 and MG160, revealed diffused
BICD2 staining throughout the cytoplasm and an
increased signal at the Golgi site in wild-type fibroblasts
compared to affected fibroblasts, in which BICD2 appeared
trapped within the fragmented Golgi. Both Golgi markers
showed massive dispersion and fragmentation in the
affected fibroblast cell lines (Figures 4D–4O and Figures013
Figure 3. Effect of the Mutant BICD2 Al-
leles on the Golgi Apparatus
(A–P) HeLa cells were transfected with
tGFP-BICD2 pCMV6-AC cDNA (either
wild-type [A–C] or with BICD2 missense
variants [D–P]). Cells were fixed and
stained for a specific Golgi marker, Giantin
(red) (1:100, Abcam), and DAPI (blue) (Life
Technologies). Only transfected cells
glowed green under the fluorescent micro-
scope and allowed an easy comparison
with untransfected cells, which reflected
the wild-type situation. For better visibil-
ity, the Giantin staining alone is shown
in the middle row and the inset in the
right row, which represents an enlarged
Golgi of a transfected cell. Scale bars repre-
sent 20 mm.
(A–C) The cells transfected with the wild-
type construct show a condensed and
abundant Golgi structure.
(D–P) Compared to wild-type or nontrans-
fected cells, cells transfected with the three
mutant cDNA constructs and the rare
variant show a fragmented Golgi with a
very diffuse and faint signal.
(Q) Quantification of cells with frag-
mented Golgi; 70–100 cells were counted
for each experiment (n¼ 3) and are shown
as the mean5 SD.S1A–S1F). Golgi fragmentation was more pronounced in
the Canadian affected individuals with the p.Thr703Met
substitution in the C-terminal coiled-coil domain than
in the Dutch affected individual with the p.Asn188Thr
substitution in the N-terminal coiled-coil domain
(Figure 4C). These functional data correlate with the
Canadian family’s more severe phenotype with contrac-
tures rather than the phenotype of the second Dutch
family, in which no contractures were seen in the affected
individuals.
Hence, BICD2 mutations in humans, flies, and mice, as
well as mutations in genes encoding some of the interac-
tion partners (dynein, dynactin, and kinesins), are associ-
ated with motor neuron diseases. This strongly supports
the view that the entire complex is crucial in proper motor
neuron functioning. Moreover, the function of the sur-
vival of motor neuron (SMN) protein that when reduced
causes proximal autosomal-recessive SMA has recently
been linked to the Golgi network. SMN interacts with
a-coatomer, which mediates vesicle trafficking between
the Golgi compartments and regulates SMN granule secre-
tion from the Golgi apparatus.44 Disruption of Golgi-medi-
ated granule secretion reduces murine Smn levels in
neuritis, suggesting that vesicular transport of Smn gran-
ules is mediated through the Golgi.45
In conclusion, our data reveal that mutations in BICD2
cause slowly progressive autosomal-dominant SMA with
weakness and atrophy of proximal and distal muscles
mainly of the legs. BICD2, a protein essential in dynein-
dynactin microtubule transport, in clathrin-mediated syn-
aptic-vesicular recycling, and in the Golgi network is thus
crucial for the functional integrity of lower motor neurons.The AmInteracting partners of BICD2 might represent good candi-
dates for the still many unsolved cases of SMA and/or
HMN.Supplemental Data
Supplemental Data include one figure and three tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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Figure 4. Mutations in BICD2 Cause Severe Golgi Fragmentation in Primary Fibroblasts
(A) Immunoblot analyses of primary-fibroblast proteins of one control cell line and two cell lines derived from affected individuals. The
cells were stained with BICD2 and b-actin as a loading control.
(B) Quantification of the immunoblot shows reduced BICD2 levels in fibroblast lines isolated from affected individuals.
(C) Golgi structures, defined as condensed, intermedium, or diffuse in 100 cells of each cell line, were counted in three independent
experiments and are given as the mean5 SD. Each quantification was done blindly by two independent persons. Statistical significance
is given between controls and each of the two cell lines as ***p < 0.001, **p < 0.01, or *p < 0.05. The following abbreviation is used: ns,
not significant.
(D–O) Immunostaining of control (D, G, J, and M) and disease (E, F, H, I, K, L, N, and O) fibroblasts with antibodies against trans-Golgi
marker p230 in green (1:100, BD Transduction Laboratories) and BICD2 in red (1:200, Sigma), as well as merged pictures, are shown. The
nucleus is stained with DAPI in blue. (M), (N), and (O) showmagnified insets of single cells from (J), (K), and (L), respectively. Note that
compared to control fibroblasts, affected fibroblasts show strongly fragmented Golgi and BICD2 trapped in the Golgi. Scale bars repre-
sent 20 mm.
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